Melatonin acts as antioxidant and improves sleep in MS patients

Neurochemical Research

Volumn 39, Issue 8, 2014, Pages 1585-1593

  Adamczyk Sowa, Monika ^a   Pierzchala, Krystyna ^a   Sowa, Pawel ^a   Mucha, Sebastian ^a   Sadowska Bartosz, Izabela ^b   Adamczyk, Jowita ^a   Hartel, Marcin ^c  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b UNIVERSITY OF RZESZÓW   (Poland)

^c MCD Voxel   (Poland)

Author keywords

Athens Insomnia Scale; Melatonin; Multiple sclerosis; Sleep; TAC; TOS

Indexed keywords

ANTIOXIDANT; MELATONIN;

ADULT; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHYSIOLOGY; PROSPECTIVE STUDY; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; YOUNG ADULT;

ADULT; ANTIOXIDANTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MELATONIN; MIDDLE AGED; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; YOUNG ADULT;

EID: 84905698632     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-014-1347-6     Document Type: Article

References (49)

1. Mehta BK (2010) New hypotheses on sunlight and the geographic variability of multiple sclerosis prevalence. J Neurol Sci 292(1-2):5-10
2. Golan D, Staun-Ram E, Glass-Marmor L, Lavi I, Rozenberg O, Dishon S, Barak M, Ish-Shalom S, Miller A (2013) The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. Brain Behav Immun 32:180-185
3. Esposito E, Cuzzocrea S (2010) Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 8(3):228-242
4. Gilgun-Sherki Y, Melamed E, Offen D (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 251:261-268 (Pubitemid 38387142)
5. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H (2011) Oxidative damage in multiple sclerosis lesions. Brain 134:1914-1924
6. Reiter RJ, Tan DX, Manchester LC, Pilar Terron M, Flores LJ, Koppisepi S (2007) Medical implications of melatonin: receptor-mediated and receptor independent actions. Adv Med Sci 52:11-28
7. Tully M, Shi R (2013) New insights in the pathogenesis of multiple sclerosis - role of acrolein in neuronal and myelin damage. Int J Mol Sci 14(10):20037-20047
8. Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX (2009) Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 15:43-50
9. Adamczyk-Sowa M, Sowa P, Pierzchala K, Polaniak R, Labuz-Roszak B (2012) Antioxidative enzymes activity and malondialdehyde concentration during mitoxantrone therapy in multiple sclerosis patients. J Physiol Pharmacol 63(6):683-690
10. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ (2007) One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 42(1):28-42 (Pubitemid 44924323)
11. Tomas-Zapico C, Coto-Montes A (2005) A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 39:99-104 (Pubitemid 41140746)
12. Kostoglou-Athanassiou I (2013) Therapeutic applications of melatonin. Ther Adv Endocrinol Metab 4(1):13-24
13. Srinivasan V, Spence DW, Trakh I, Pandi-Perumal SR, Cardinali DP, Maestroni GJ (2008) Immunomodulation by melatonin: its significance for seasonally occurring diseases. NeuroImmunoModulation 15:93-101
14. Bøe Lunde HM, Aae TF, Indrevåg W, Aarseth J, Bjorvatn B, Myhr KM, Bø L (2012) Poor sleep in patients with multiple sclerosis. PLoS ONE 7(11):e49996. doi:10.1371/journal.pone.0049996
15. Côté I, Trojan DA, Kaminska M, Cardoso M, Benedetti A, Weiss D, Robinson A, Bar-Or A, Lapierre Y, Kimoff RJ (2013) Impact of sleep disorder treatment on fatigue in multiple sclerosis. Mult Scler 19(4):480-489
16. Bamer AM, Johnson KL, Amtmann D, Kraft GH (2008) Prevalence of sleep problems in individuals with multiple sclerosis. Mult Scler 14:1127-1130
17. Caminero A, Bartolome M (2011) Sleep disturbances in multiple sclerosis. J Neurol Sci 309:86-91
18. Hagan RM, Oakley NR (1995) Melatonin comes of age? Trends Pharmacol Sci 16(3):81-83
19. Hedstrom AK, Akerstedt T, Hillert J, Olsson T, Alfredsson L (2011) Shift work at young age is associated with increased risk for multiple sclerosis. Ann Neurol 70:733-741
20. Ghorbani A, Salari M, Shaygannejad V, Norouzi R (2013) The role of melatonin in the pathogenesis of multiple sclerosis: a case-control study. Int J Prev Med 4(Suppl 2):S180-S184
21. Villapol S, Fau S, Renolleau S, Biran V, Charriaut-Marlangue C, Baud O (2011) Melatonin promotes myelination by decreasing white matter inflammation after neonatal stroke. Pediatr Res 69(1):51-55
22. Akpinar Z, Tokgöz S, Gökbel H, Okudan N, Uǧuz F, Yilmaz G (2008) The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. Psychiatry Res 161(2):253-257
23. Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58:840-846 (Pubitemid 41746873)
24. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
25. Erel O (2005) A new automated colorimetric method for measuring total oxidant status. Clin Biochem 38:1103-1111
26. Erel O (2004) A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37:277-285
27. Soldatos CR, Dikeos DG, Paparrigopoulos TJ (2000) Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res 48:555-556
28. Fornal-Pawłowska M, Wołyńczyk-Gmaj D, Szelenberger W (2011) Validation of the Polish version of the Athens Insomnia Scale. Psychiatr Pol 45(2):211-221
29. Beck AT, Steer RA, Ball R, Ranieri W (1996) Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients. J Pers Assess 67(3):588-597 (Pubitemid 26382973)
30. Parnowski T, Jernajczyk W (1977) Inwentarz Depresji Becka w ocenie nastroju osób zdrowych i chorych na choroby afektywne. Psychiatr Pol 11(4):417-421
31. Sadowska-Bartosz I, Adamczyk-Sowa M, Galiniak S, Mucha S, Pierzchala K, Bartosz G (2013) Oxidative modification of serum proteins in multiple sclerosis. Neurochem Int 63(5):507-516
32. Davitashvili D, Beridze M, Shakarishvili R, Kiziria M, Sanikidze T (2012) The role of endogenous antiradical protective system in multiple sclerosis. Georgian Med News 205:11-19
33. Choi IY, Lee SP, Denney DR, Lynch SG (2011) Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T. Mult Scler 17(3):289-296
34. Miller E, Mrowicka M, Saluk-Juszczak J, Ireneusz M (2011) The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem Res 36(6):1012-1016
35. Miller E, Mrowicka M, Malinowska K, Kedziora J, Majsterek I (2011) The effects of whole-body cryotherapy and melatonin supplementation on total antioxidative status and some antioxidative enzymes in multiple sclerosis patients. Pol Merkur Lekarski 183:150-153
36. Miller E, Walczak A, Majsterek I, Kȩdziora J (2013) Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course. J Neuroimmunol 257(1-2):97-101
37. Bakshi R, Thompson AJ, Rocca MA, Pelletier D, Dousset V, Barkhof F, Inglese M, Guttmann CR, Horsfield MA, Filippi M (2008) MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 7(7):615-625
38. Minagar A (2013) Current and future therapies for multiple sclerosis. Scientifica (Cairo) 2013:249101. doi:10.1155/2013/249101
39. Witte ME, Mahad DJ, Lassmann H, van Horssen J (2014) Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends Mol Med 20(3):179-187
40. Sathornsumetee S, McGavern DB, Ure DR, Rodriguez M (2000) Quantitative ultrastructural analysis of a single spinal cord demyelinated lesion predicts total lesion load, axonal loss, and neurological dysfunction in a murine model of multiple sclerosis. Am J Pathol 157:1365-1376
41. Melamud L, Golan D, Luboshitzky R, Lavi I, Miller A (2012) Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J Neurol Sci 314:37-40
42. Najafi MR, Toghianifar N, Etemadifar M, Haghighi S, Maghzi AH, Akbari M (2013) Circadian rhythm sleep disorders in patients with multiple sclerosis and its association with fatigue: a case-control study. J Res Med Sci 18(Suppl 1):S71-S73
43. Pokryszko-Dragan A, Bilińska M, Gruszka E, Biel Ł, Kamińska K, Konieczna K (2013) Sleep disturbances in patients with multiple sclerosis. Neurol Sci 34(8):1291-1296
44. Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH (2002) Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry 159(11):1862-1868 (Pubitemid 35283251)
45. Papuc E, Stelmasiak Z (2012) Factors predicting quality of life in a group of polish subjects with multiple sclerosis: accounting for functional state, socio-demographic and clinical factors. Clin Neurol Neurosurg 114(4):341-346
46. Arnett PA, Randolph JJ (2006) Longitudinal course of depression symptoms in multiple sclerosis. J Neurol Neurosurg Psychiatry 77:606-610
47. Pandya R, Patten S (2002) Depression in multiple sclerosis associated with interferon beta-1a (Rebif). Can J Psychiatry 47(7):686 (Pubitemid 35192039)
48. Kirzinger SS, Jones J, Siegwald A, Crush AB (2013) Relationship between disease-modifying therapy and depression in multiple sclerosis. Int J MS Care 15(3):107-112
49. Muxel SM, Pires-Lapa MA, Monteiro AW, Cecon E, Tamura EK, Floeter-Winter LM, Markus RP (2012) NF-κB drives the synthesis of melatonin in RAW 264.7 macrophages by inducing the transcription of the arylalkylamine-N- acetyltransferase (AA-NAT) gene. PLoS ONE 7(12):e52010